Document Detail


Ibuprofen treatment for closure of patent ductus arteriosus is not associated with increased risk of neuropathology.
MedLine Citation:
PMID:  20581742     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ibuprofen is an effective pharmacological intervention for closure of a patent ductus arteriosus (PDA) in preterm infants and is an alternative to surgical ligation; however, it is not certain whether ibuprofen treatment is associated with adverse effects on the brain. Therefore, this study examined neuropathological outcomes of ibuprofen therapy for a PDA. Fetal baboons were delivered at 125 d of gestation (dg; term ∼185 dg) by caesarean section, given surfactant, and ventilated for 14 d with positive pressure ventilation (PPV). Baboons were randomly allocated to receive either ibuprofen (PPV+ ibuprofen, n = 8) or no therapy (PPV, n = 5). Animals were killed on day 14 and brains assessed for cerebral growth, development, and neuropathology. Body and brain weights, the total volume of the brain, and the surface folding index (measure of brain growth) were not different (p > 0.05) between PPV+ ibuprofen-treated and PPV animals. There was no difference (p > 0.05) in the number of myelin basic protein-immunoreactive (IR) oligodendrocytes, glial fibrillary acid protein-IR astrocytes, or Iba1-IR macrophages/microglia in the forebrain. No overt cerebellar alterations were observed in either group. Ibuprofen treatment for PDA closure in the preterm baboon neonate is not associated with any increased risk of neuropathology or alterations to brain growth and development.
Authors:
Michelle Loeliger; Amy Shields; Donald McCurnin; Ronald I Clyman; Bradley Yoder; Terrie E Inder; Sandra M Rees
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Pediatric research     Volume:  68     ISSN:  1530-0447     ISO Abbreviation:  Pediatr. Res.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-16     Completed Date:  2011-01-11     Revised Date:  2014-09-18    
Medline Journal Info:
Nlm Unique ID:  0100714     Medline TA:  Pediatr Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  298-302     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Animals, Newborn
Astrocytes / drug effects,  metabolism
Brain / drug effects*,  growth & development,  metabolism,  pathology
Cyclooxygenase Inhibitors / adverse effects,  pharmacology*
Disease Models, Animal
Ductus Arteriosus, Patent / drug therapy*
Gestational Age
Glial Fibrillary Acidic Protein / metabolism
Ibuprofen / adverse effects,  pharmacology*
Macrophages / drug effects,  metabolism
Microglia / drug effects,  metabolism
Papio
Positive-Pressure Respiration
Premature Birth
Pulmonary Surfactants / pharmacology
Time Factors
Grant Support
ID/Acronym/Agency:
HL46691/HL/NHLBI NIH HHS; HL52636/HL/NHLBI NIH HHS; HL52646/HL/NHLBI NIH HHS; HL56061/HL/NHLBI NIH HHS; HL77395/HL/NHLBI NIH HHS; R01 HL074942/HL/NHLBI NIH HHS; R01 HL074942/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Cyclooxygenase Inhibitors; 0/Glial Fibrillary Acidic Protein; 0/Pulmonary Surfactants; WK2XYI10QM/Ibuprofen
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patterns of gene expression in the ductus arteriosus are related to environmental and genetic risk f...
Next Document:  Identification of GATA6 sequence variants in patients with congenital heart defects.